

RESEARCH ARTICLE

# Brain natriuretic peptide (BNP) may play a major role in risk stratification based on cerebral oxygen saturation by near-infrared spectroscopy in patients undergoing major cardiovascular surgery

Hiroshi Mukaida<sup>1,2\*</sup>, Masakazu Hayashida<sup>3</sup>, Satoshi Matsushita<sup>1</sup>, Makiko Yamamoto<sup>3</sup>, Atsushi Nakamura<sup>4</sup>, Atsushi Amano<sup>1</sup>

**1** Department of Cardiovascular Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan, **2** Department of Clinical Engineering, Juntendo University Hospital, Tokyo, Japan, **3** Department of Anesthesiology & Pain Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan, **4** Department of Clinical Engineering, Kyorin University Faculty of Health Sciences, Tokyo, Japan

\* [me-da@juntendo.ac.jp](mailto:me-da@juntendo.ac.jp)



**OPEN ACCESS**

**Citation:** Mukaida H, Hayashida M, Matsushita S, Yamamoto M, Nakamura A, Amano A (2017) Brain natriuretic peptide (BNP) may play a major role in risk stratification based on cerebral oxygen saturation by near-infrared spectroscopy in patients undergoing major cardiovascular surgery. PLoS ONE 12(7): e0181154. <https://doi.org/10.1371/journal.pone.0181154>

**Editor:** Claudio Passino, Ospedale del Cuore G Pasquinucci Fondazione Toscana Gabriele Monasterio di Massa, ITALY

**Received:** February 28, 2017

**Accepted:** June 27, 2017

**Published:** July 12, 2017

**Copyright:** © 2017 Mukaida et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** The authors received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

## Abstract

### Purpose

A previous study reported that low baseline cerebral oxygen saturation (ScO<sub>2</sub>) ( $\leq 50\%$ ) measured with near-infrared spectroscopy was predictive of poor clinical outcomes after cardiac surgery. However, such findings have not been reconfirmed by others. We conducted the current study to evaluate whether the previous findings would be reproducible, and to explore mechanisms underlying the ScO<sub>2</sub>-based outcome prediction.

### Methods

We retrospectively investigated 573 consecutive patients, aged 20 to 91 (mean  $\pm$  standard deviation, 67.1  $\pm$  12.8) years, who underwent major cardiovascular surgery. Preanesthetic baseline ScO<sub>2</sub>, lowest intraoperative ScO<sub>2</sub>, various clinical variables, and hospital mortality were examined.

### Results

Bivariate regression analyses revealed that baseline ScO<sub>2</sub> correlated significantly with plasma brain natriuretic peptide concentration (BNP), hemoglobin concentration (Hgb), estimated glomerular filtration rate (eGFR), and left ventricular ejection fraction (LVEF) ( $p < 0.0001$  for each). Baseline ScO<sub>2</sub> correlated with BNP in an exponential manner, and BNP was the most significant factor influencing ScO<sub>2</sub>. Logistic regression analyses revealed that baseline and lowest intraoperative ScO<sub>2</sub> values, but not relative ScO<sub>2</sub> decrements, were significantly associated with hospital mortality ( $p < 0.05$ ), independent of the EuroSCORE ( $p < 0.01$ ). Receiver operating curve analysis of ScO<sub>2</sub> values and hospital mortality revealed an area under the curve (AUC) of 0.715 ( $p < 0.01$ ) and a cutoff value of  $\leq 50.5\%$  for the baseline

and  $ScO_2$ , and an AUC of 0.718 ( $p < 0.05$ ) and a cutoff value of  $\leq 35\%$  for the lowest intraoperative  $ScO_2$ . Low baseline  $ScO_2$  ( $\leq 50\%$ ) was associated with increases in intubation time, intensive care unit stay, hospital stay, and hospital mortality.

## Conclusion

Baseline  $ScO_2$  was reflective of severity of systemic comorbidities and was predictive of clinical outcomes after major cardiovascular surgery.  $ScO_2$  correlated most significantly with BNP in an exponential manner, suggesting that BNP plays a major role in the  $ScO_2$ -based outcome prediction.

## Introduction

Tissue oximetry by near-infrared spectroscopy (NIRS) is widely used to monitor cerebral oxygen saturation ( $ScO_2$ ) during cardiovascular surgery [1, 2]. Usefulness of intraoperative  $ScO_2$  monitoring has been reported by many studies [3–12]. However, significance of absolute  $ScO_2$  values has not been established, since they are influenced by multiple factors such as a composition of focal arterial/venous blood components, oxygen saturation in extra-cerebral tissues, blood hemoglobin concentration (Hgb), and the skull thickness [2, 13–17]. In addition,  $ScO_2$  values derived from different NIRS devices can differ even within the same subjects [14, 15, 17, 18]. Therefore,  $ScO_2$  currently is used as a trend monitor rather than as an absolute index of cerebral oxygenation [2]. Intraoperatively, a relative decrease in  $ScO_2$  from baseline (e.g., 20% decrease) or an absolute threshold  $ScO_2$  (e.g.,  $< 50\%$ ) has been used as provisional criteria for cerebral desaturation [1]. However, extremely wide variations in baseline  $ScO_2$  values ranging from less than 20% to more than 80% have been reported [16–18]. Such wide variations seemed unlikely to be explained by aforementioned influencing factors alone. Therefore, it seemed necessary to explore if any factors that might more profoundly influence  $ScO_2$ .

Reportedly, patients with cardiac dysfunction and those with renal failure show lower  $ScO_2$  than usual [10, 19, 20–23]. In line with these studies, Heringlake et al. showed that  $ScO_2$  significantly correlated with age, Hgb, N-terminal pro-brain natriuretic peptide (NTproBNP), estimated glomerular filtration rate (eGFR), and left ventricular ejection fraction (LVEF) [24].  $ScO_2$  values thus could be associated with risk factors, such as cardiac dysfunction [10, 19, 20, 21, 24], renal dysfunction [21–24], age [24], and anemia [16, 17, 21, 24]. Consequently, Heringlake et al. showed that the baseline  $ScO_2$  could be predictive of morbidity and mortality after cardiac surgery [24]. However, their findings have not been reconfirmed by other investigators. In addition, although they showed a negative correlation between NTproBNP and  $ScO_2$ , a relationship between brain natriuretic peptide (BNP) and  $ScO_2$  has not been reported. BNP is an active hormone released from the heart in response to cardiac overloads, whereas NTproBNP is an inactive fragment of precursor proBNP [25]. Because a number of studies showed that compared with NTproBNP, BNP better correlated with indices of cardiac function [26, 27], better detected cardiac dysfunction [28], and better predicted progression of cardiac disease [29], BNP may better correlate with  $ScO_2$ , compared with NTproBNP reported previously [24].

The current study was conducted to examine whether the risk prediction by baseline  $ScO_2$  values would be reproducible, and to closely characterize the relationship between BNP and  $ScO_2$ , which might contribute to wide inter-individual variations in baseline  $ScO_2$  values.

## Materials and methods

Prior to the current study, approval was obtained from the Institutional Review Board (IRB) of Juntendo University Hospital. Because of the anonymous and retrospective fashion of the study, the IRB waived the need for patient consent.

### Patients

The current retrospective study included 573 consecutive adult patients, aged 20–91 (mean  $\pm$  standard deviation,  $67.1 \pm 12.8$ ) years, who underwent major on-pump or off-pump cardiovascular surgery with ScO<sub>2</sub> monitoring at Juntendo University Hospital from January 2014 to April 2015.

### Data collection

ScO<sub>2</sub> was monitored at the bilateral forehead using the INVOS5100C device (Medtronic, Minneapolis, MN). ScO<sub>2</sub> data were automatically stored every 5–6 seconds in the USB memory stick attached to the device. The baseline ScO<sub>2</sub> was determined by averaging the bilateral ScO<sub>2</sub> readings that had been recorded before induction of general anesthesia while patients were breathing room air in a resting position. In addition, the lowest intraoperative ScO<sub>2</sub> was identified in each patient, and relative decrements in ScO<sub>2</sub> from baseline were calculated as the maximal drop in ScO<sub>2</sub> (= the baseline ScO<sub>2</sub> – the lowest intraoperative ScO<sub>2</sub>) and % maximal drop in ScO<sub>2</sub> (= the maximal ScO<sub>2</sub> drop / the baseline ScO<sub>2</sub> \* 100).

Besides demographic variables serving as potential risk factors, the specific cardiovascular risk factors were assessed, including Hgb, BNP, eGFR, LVEF, and the logistic EuroSCORE II as an established risk analysis model [30, 31], using the previous study as a reference [24]. Clinical outcome data included postoperative intubation time, intensive care unit (ICU) stay, hospital stay, postoperative stroke, and hospital mortality.

### Statistical analysis

Because all continuous variables were non-normally distributed after Shapiro-Wilk testing, they are shown as median and quartiles. Categorical data are shown as numbers (%). Because BNP and the EuroSCORE were non-normally distributed in extreme ways, their log-normal transformed values also were used for statistical analyses. Spearman's correlation coefficient was used to identify factors associated with the baseline ScO<sub>2</sub>. However, Pearson's correlation coefficient also was used to select candidate variables for multivariate regression analysis, and also to closely illustrate relationships between BNP and the baseline ScO<sub>2</sub> and that between the EuroSCORE and the baseline ScO<sub>2</sub>. Multiple regression analysis was used to determine factors that could significantly influence the baseline ScO<sub>2</sub>. Bivariate and multivariate logistic regression analyses were used to examine whether the EuroSCORE, absolute ScO<sub>2</sub> values, and relative ScO<sub>2</sub> decrements could be predictors of hospital mortality, as described previously [9, 24]. The best cutoff values for significant predictors were further determined by receiver operating characteristic (ROC) analysis, as described previously [9, 24].

Patients were divided into 2 groups based on whether they remained alive or were deceased during hospitalization. In addition, patients were divided into 2 groups also based on whether their baseline ScO<sub>2</sub> values were  $\leq 50\%$  or  $> 50\%$ , according to the criterion logically set by Heringlake et al [24]. The groups were compared with Mann-Whitney *U* test and Fisher's exact test, as appropriate. A *p* value  $< 0.05$  was considered significant. Data were analyzed with the software program JMP12 (SAS Institute. Cary, NC).

## Results

### Patients' characteristics

Characteristics of the 573 patients in the total cohort are shown in Table 1. Notably, the baseline ScO<sub>2</sub> before oxygenation and induction of general anesthesia ranged extremely widely from 31.5% to 90.5% (see Figs 1 & 2).


**Table 1. Patients' characteristics, surgical procedures, and mortality in 573 patients.**

Patients' characteristics	Total Cohort n = 573	Hospital Mortality		Significance
		Alive n = 561 (97.9%)	Deceased n = 12 (2.1%)	
<b>Demographic data</b>				
Female	205 (35.8%)	201 (36.5%)	4 (33.3%)	
Age	69 (61–77)	69 (61–77)	74 (71–79)	NS
BSA (m <sup>2</sup> )	1.65 (1.5–1.78)	1.66 (1.5–1.78)	1.6 (1.48–1.68)	NS
<b>History</b>				
CKD5D	34 (5.9%)	31 (5.5%)	3 (25%)	p < 0.05
Hypertension	358 (62.4%)	349 (62.2%)	9 (75%)	NS
Dyslipidemia	234 (40.8%)	229 (40.8%)	5 (41.7%)	NS
DM	137 (23.9%)	133 (23.8%)	4 (33.3%)	NS
COPD	57 (9.9%)	57 (9.9%)	0	NS
<b>Risk stratification</b>				
NYHAIII/IV	53 (9.3%)	50 (8.9%)	3 (25%)	NS
EuroSCORE (%)	2.13 (1.15–4.52)	2.06 (1.14–4.26)	9.79 (5.64–18.3)	p < 0.0001
<b>Preoperative data</b>				
BNP (pg/mL)	88.7 (34.3–209.3)	86 (33.4–203.1)	288.5 (59.6–2159)	p < 0.05
Hgb (g/dL)	13 (11.6–14.1)	13 (11.6–14.2)	11.5 (10.7–13.8)	NS
eGFR (mL/min/1.73m <sup>2</sup> )	66.8 (50–81.9)	67.1 (51.2–82.1)	30.5 (14.9–67)	p < 0.01
LVEF (%)	64 (55–70)	64 (55–70)	62 (41.2–71)	NS
Baseline ScO <sub>2</sub> (%)	63.8 (57.5–69.5)	64 (58–69.5)	54.2 (44.4–62.2)	p < 0.01
<b>Surgical procedures</b>				
On-pump CABG	12 (2.1%)	11 (2%)	1 (8.3%)	
CABG + TA replacement	6 (1.1%)	6 (1.1%)	0	
Valve	233 (40.7%)	229 (40.8%)	4 (33.3%)	
Valve + CABG	60 (10.5%)	55 (9.8%)	5 (41.7%)	
Valve + TA replacement	73 (12.7%)	73 (13%)	0	
Valve + CABG + TA replacement	6 (1.1%)	6 (1.1%)	0	
TA replacement	35 (6.1%)	33 (5.9%)	2 (16.7%)	
Myxoma	6 (1.1%)	6 (1.1%)	0	
Adult Congenital	11 (1.9%)	11 (2%)	0	
Off-pump CABG	131 (22.9%)	131 (23.4%)	0	
<b>Operative course</b>				
Duration of surgery (min)	236 (174–316)	236 (175–315)	236 (124–401)	NS

Data are expressed as median (quartiles) or numbers (%).

BSA, body surface area; CKD5D, chronic kidney disease, stage 5D; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association grading; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass grafting; TA, thoracic aortic; BNP, brain natriuretic peptide; Hgb, hemoglobin; eGFR, estimated glomerular filtration rate; ScO<sub>2</sub>, baseline cerebral oxygen saturation.

<https://doi.org/10.1371/journal.pone.0181154.t001>



**Fig 1. Relationships of BNP, logarithmic BNP, EuroSCORE, and logarithmic EuroSCORE to baseline ScO<sub>2</sub>.** Relationships between BNP and baseline ScO<sub>2</sub> (A), between logarithmic BNP and baseline ScO<sub>2</sub> (B), between EuroSCORE and baseline ScO<sub>2</sub> (C), and between logarithmic EuroSCORE and baseline ScO<sub>2</sub> (D) are shown. Pearson's correlation coefficients (r) and p values are depicted in each panel. Exponential regression lines, in addition to linear regression lines, are depicted in left panels (A and C). BNP, brain natriuretic peptide; ScO<sub>2</sub>, cerebral oxygen saturation.


<https://doi.org/10.1371/journal.pone.0181154.g001>

### Factors influencing baseline ScO<sub>2</sub>

By both Spearman's and Pearson's correlation coefficients, the baseline ScO<sub>2</sub> correlated highly significantly with logarithmic BNP or BNP, Hgb, eGFR, age, LVEF, and BSA ( $p < 0.0001$  for each) (Table 2). By Pearson's correlation analysis, the baseline ScO<sub>2</sub> correlated more closely with logarithmic BNP than with BNP, indicating that the baseline ScO<sub>2</sub> correlated with BNP in an exponential rather than linear manner (Fig 1A and 1B). On the other hand, the baseline ScO<sub>2</sub> correlated with Hgb, eGFR, BSA, and LVEF in linear manners (Fig 2). The multiple linear regression analysis revealed that logarithmic BNP, Hgb, eGFR, LVEF, and BSA, but not age, remained significant influencing factors of the baseline ScO<sub>2</sub>, and that logarithmic BNP was the most significant influencing factor (Table 2).

### Baseline ScO<sub>2</sub>, mortality, and morbidity

Results of the group comparisons between patients alive ( $n = 561$ ) and deceased ( $n = 12$ ) are shown in Table 1. In the total cohort, the predicted mortality estimated by the EuroSCORE



**Fig 2. Relationships of Hgb, eGFR, BSA, and LVEF to baseline ScO<sub>2</sub>.** Relationships between Hgb and baseline ScO<sub>2</sub> (A), between eGFR and baseline ScO<sub>2</sub> (B), between BSA and baseline ScO<sub>2</sub> (C), and between LVEF and baseline ScO<sub>2</sub> (D) are shown. Pearson's correlation coefficient (r) and a p value are depicted in each panel. Hgb, hemoglobin; eGFR, estimate glomerular filtration rate; BSA, body surface area; LVEF, left ventricular ejection fraction; ScO<sub>2</sub>, cerebral oxygen saturation.

<https://doi.org/10.1371/journal.pone.0181154.g002>

**Table 2. Results of bivariate and multivariate regression analyses for the baseline ScO<sub>2</sub>.**

Variables	Spearman's correlation coefficient		Pearson's correlation coefficient		Standardized partial regression coefficient R <sup>2</sup> = 0.43 (p < 0.0001)	
	Spearman's ρ	p value	Pearson's r	p value	β	p value
Age	-0.25	p < 0.0001	-0.26	p < 0.0001	0.003	NS
BSA	0.23	p < 0.0001	0.23	p < 0.0001	0.025	p < 0.05
Hgb	0.44	p < 0.0001	0.42	p < 0.0001	0.208	p < 0.0001
Logarithmic BNP	-0.58	p < 0.0001	-0.59	p < 0.0001	-0.417	p < 0.0001
eGFR	0.36	p < 0.0001	0.37	p < 0.0001	0.14	p < 0.0001
LVEF	0.23	p < 0.0001	0.23	p < 0.0001	0.092	p < 0.01

ScO<sub>2</sub>, cerebral oxygen saturation; BSA, body surface area; Hgb, hemoglobin; BNP, brain natriuretic peptide; eGFR, estimate glomerular filtration rate; LVEF, left ventricular ejection fraction.

<https://doi.org/10.1371/journal.pone.0181154.t002>

**Table 3. Comparison of risk factors, morbidity, and hospital mortality between 2 groups according to the baseline ScO<sub>2</sub> values.**

	Baseline ScO <sub>2</sub> ≤50%	Baseline ScO <sub>2</sub> >50%	p values
	n = 45	n = 528	
Age	74 (66–79)	69 (61–76)	p < 0.05
BSA	1.57 (1.43–1.72)	1.66 (1.51–1.79)	p < 0.05
Hgb	11.5 (9.9–13)	13 (11.7–14.2)	p < 0.0001
BNP (pg/dL)	406.9 (213.2–1767.5)	75.1 (31.8–179.5)	p < 0.0001
eGFR (mL/min/1.73m <sup>2</sup> )	45.2 (5.4–62.2)	69 (53.3–83.3)	p < 0.0001
LVEF%	61 (46–66)	65 (55–70)	p < 0.05
EuroSCORE	5.29 (2.77–10.98)	1.99 (1.1–3.97)	p < 0.0001
Intubation time (h)	8 (5.6–16)	6 (4–10.5)	p < 0.01
ICU stay (days)	4 (2–7.5)	2 (1–3)	p < 0.0001
Postoperative hospital stay (days)	16 (11.5–24)	12 (9–18)	p < 0.001
Postoperative stroke	0 (0%)	15 (2.84%)	NS
Hospital mortality	5 (11.1%)	7 (1.3%)	p < 0.01

Data are expressed as median (quartiles) or numbers (%).

ScO<sub>2</sub>, cerebral oxygen saturation; BSA, body surface area; Hgb, hemoglobin; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; ICU, intensive care unit.


<https://doi.org/10.1371/journal.pone.0181154.t003>

was 2.13 (1.15–4.52) %, while the actual hospital mortality was 2.09% (12/573) (Table 1). The number of patients with end-stage chronic kidney disease (CKD) was significantly more in deceased patients. The EuroSCORE, and BNP were significantly higher, while eGFR and the baseline ScO<sub>2</sub> were significantly lower in deceased patients. Age, Hgb, BSA and LVEF were not different between these patients (Table 1).

Results of the group comparisons according to the baseline ScO<sub>2</sub> are shown in Table 3. Age, BNP, and the EuroSCORE were significantly higher, while BSA, Hgb, eGFR, and LVEF were significantly lower in patients with ScO<sub>2</sub> ≤50% (n = 528) compared to those with ScO<sub>2</sub> >50% (n = 45) (Table 3). Postoperative intubation time, ICU stay, and hospital stay were significantly longer, and hospital mortality was significantly higher in patients with ScO<sub>2</sub> ≤50% compared to those with ScO<sub>2</sub> >50%, although the incidence of postoperative stroke did not differ between them (Table 3).

### Prediction of hospital mortality by EuroSCORE, absolute ScO<sub>2</sub> values, and relative ScO<sub>2</sub> decrements

Bivariate logistic regression analyses revealed that hospital mortality was significantly associated with the EuroSCORE (p = 0.0005), the baseline ScO<sub>2</sub> (p = 0.0031), and the lowest intraoperative ScO<sub>2</sub> (p = 0.018), respectively, but not with the maximal drop in ScO<sub>2</sub> (p = 0.8928) nor % maximal drop in ScO<sub>2</sub> (p = 0.5666), indicating that the EuroSCORE and the two absolute ScO<sub>2</sub> values, but not relative ScO<sub>2</sub> decrements, could be predictors of hospital mortality. The multivariate logistic regression analysis incorporating the EuroSCORE and the baseline ScO<sub>2</sub> as independent variables revealed that hospital mortality was significantly associated with both of the EuroSCORE and the baseline ScO<sub>2</sub> (chi-square 16.3 [p = 0.0003] for overall model fit; odds ratio 1.076 [95% CI, 1.024–1.127; p = 0.0059] for the EuroSCORE; odds ratio 0.937 [95% CI, 0.882–0.997; p = 0.0417] for the baseline ScO<sub>2</sub>). Likewise, the analysis incorporating the EuroSCORE and the lowest intraoperative ScO<sub>2</sub> revealed that hospital mortality was significantly associated with both of the EuroSCORE and the lowest intraoperative ScO<sub>2</sub> (chi-



**Fig 3. Results of ROC analyses of EuroSCORE, baseline ScO<sub>2</sub>, and lowest intraoperative ScO<sub>2</sub> for predicting hospital mortality.** Areas under curves (AUCs) and p values were 0.883 (95% CI, 0.806–0.932;  $p < 0.0001$ ) for the EuroSCORE, 0.715 (95% CI, 0.508–0.859;  $p < 0.01$ ) for the baseline ScO<sub>2</sub>, and 0.718 (95% CI, 0.577–0.826;  $p = 0.0160$ ) for the lowest intraoperative ScO<sub>2</sub>, respectively. ROC, receiver operating curve; ScO<sub>2</sub>, cerebral oxygen saturation.

<https://doi.org/10.1371/journal.pone.0181154.g003>

square 16.9 [ $p = 0.0002$ ] for overall model fit; odds ratio 1.097 [95% CI, 1.044–1.150;  $p = 0.0001$ ] for the EuroSCORE; odds ratio 0.948 [95% CI, 0.903–0.995;  $p = 0.0275$ ] for the lowest intraoperative ScO<sub>2</sub>). These indicated that each of baseline and lowest intraoperative ScO<sub>2</sub> values could be predictors of hospital mortality, independent of the EuroSCORE.

## Cutoff values of EuroSCORE, baseline ScO<sub>2</sub>, and lowest intraoperative ScO<sub>2</sub> for predicting hospital mortality

ROC analysis of the EuroSCORE and hospital mortality revealed an area under the curve (AUC) of 0.883 (95% CI, 0.806–0.932;  $p < 0.0001$ ) and a cutoff value of  $\geq 3.25\%$  (sensitivity 100%, specificity 67.5%) (Fig 3). That of the baseline ScO<sub>2</sub> and hospital mortality revealed an AUC of 0.715 (95% CI, 0.508–0.859;  $p = 0.0024$ ) and a cutoff value of  $\leq 50.5\%$  (sensitivity 50.0%, specificity 92.2%) (Fig 3). That of the lowest intraoperative ScO<sub>2</sub> and hospital mortality revealed an AUC of 0.718 (95% CI, 0.577–0.826;  $p = 0.0160$ ) and a cutoff value of  $\leq 35\%$  (sensitivity 58.3%, specificity 81.5%) (Fig 3). The EuroSCORE tended to have a better accuracy in predicting hospital mortality compared to the baseline ScO<sub>2</sub> and the lowest intraoperative ScO<sub>2</sub>, but the differences did not reach a statistical significance (differences between areas, 0.168,  $p = 0.0522$ ; and 0.165,  $p = 0.0535$ , respectively).

## Relationship between EuroSCORE and baseline ScO<sub>2</sub>

Similarly to the relationship between BNP and the baseline ScO<sub>2</sub>, the baseline ScO<sub>2</sub> correlated more closely with the logarithmic EuroSCORE than the EuroSCORE, indicating that ScO<sub>2</sub> correlated with the EuroSCORE in an exponential rather than linear manner (Fig 1C and 1D). Despite the close correlation between the EuroSCORE and the baseline ScO<sub>2</sub>, both could be independent predictors of hospital mortality, as mentioned above.

## Discussion

### Factors influencing baseline ScO<sub>2</sub>

We found that the baseline ScO<sub>2</sub> correlated closely with BNP or logarithmic BNP, Hgb, eGFR, LVEF, BSA, and age by bivariate correlation analyses. Previous studies reported that ScO<sub>2</sub> significantly correlated with Hgb, NTproBNP, eGFR, LVEF, age, and variables associated with body size [16, 17, 20, 21, 24]. To our knowledge, the current study was the first one that demonstrated a significant correlation between BNP and ScO<sub>2</sub>, although Heringlake et al. reported that between NTproBNP and ScO<sub>2</sub> [24]. Our findings were basically in good agreement with their findings. However, we found a much closer correlation between BNP and ScO<sub>2</sub> ( $\rho = -0.58$ ,  $p < 0.0001$ ) compared to that between Hgb and ScO<sub>2</sub> ( $\rho = 0.44$ ,  $p < 0.0001$ ), in contrast to similar correlation coefficients for Hgb ( $\rho = 0.37$ ,  $p < 0.0001$ ) and NTproBNP ( $\rho = -0.35$ ,  $p < 0.0001$ ) reported by the previous study [24]. Such a slight difference might result most likely from a difference in patients' populations studied, but might result also from a difference in peptides examined, since a number of studies showed that compared with NTproBNP, BNP better correlated with cardiac indices [26–29], although some studies reported equal performance of NTproBNP and BNP [32].

In the current study, ScO<sub>2</sub> correlated with Hgb, eGFR, BSA, and LVEF in linear manners. In contrast, ScO<sub>2</sub> correlated with BNP in an exponential manner. Possibly, this exponential relationship reflected biologic features of BNP, since previous studies analyzed relationships between BNP and cardiac indices with Pearson's correlation after log-transforming BNP or with exponential models, indicating that these relationships were better expressed in exponential rather than linear manners [26, 27, 33]. Consequently, we used logarithmic BNP instead of BNP in multiple regression analysis, and found that logarithmic BNP, Hgb, eGFR, LVEF, and BSA, but not age, remained significant factors that were associated with the baseline ScO<sub>2</sub>, and that logarithmic BNP was the most significant factor. BNP was most significantly associated with the baseline ScO<sub>2</sub> possibly because BNP acted as a surrogate of cardiorenal function that could closely affect baseline ScO<sub>2</sub> values via its effects on cerebral blood flow and/or

cerebrovascular pathology [10, 19, 20, 22, 23]. Our findings also suggested that BNP could be the most significant factor that contributed to the wide inter-individual variations in baseline ScO<sub>2</sub> values.

### Usefulness of baseline ScO<sub>2</sub> in risk stratification

As reported previously [24], there was a close correlation between the baseline ScO<sub>2</sub> and the EuroSCORE. Interestingly, ScO<sub>2</sub> correlated with the EuroSCORE in an exponential manner. The reason for such a relationship was unclear, but this might be related to the formula for calculating the logistic EuroSCORE, which uses logistic regression analysis incorporating exponential functions in its formula [30].

Because low ScO<sub>2</sub> values were associated with high BNP, low Hgb, low eGFR, low LVEF, and the high EuroSCORE, low baseline ScO<sub>2</sub> values might be reflective of severe comorbidities and thus predictive of poor prognosis, as reported previously [24]. Indeed, we found that the baseline ScO<sub>2</sub> was significantly less in patients deceased than alive. Further, the baseline ScO<sub>2</sub> ≤50% was associated with increases in intubation time, ICU stay, hospital stay, and hospital mortality. Further, the logistic regression analysis revealed that ScO<sub>2</sub> could predict hospital mortality independent of the EuroSCORE. The ROC analysis revealed that a cutoff value for the baseline ScO<sub>2</sub> in predicting hospital mortality was 50.5%, which was very close to the cutoff value of 51% reported previously [24]. As described above, we found the most significant correlation between BNP and ScO<sub>2</sub>. Further, previous studies reported a significant role of BNP in predicting prognosis of cardiac disease [29, 34, 35]. Taken together, it seemed conceivable that BNP played a major role in risk prediction based on the baseline ScO<sub>2</sub>. Heringlake et al. found that a low baseline ScO<sub>2</sub> value (≤50%) by itself could be predictive of postoperative mortality [24], and we could steadily reconfirm their findings. Hence, it seemed highly likely that cerebral oximetry could have a significant role in risk stratification in patients undergoing cardiovascular surgery. Further, our data suggested that preoperative cerebral oximetry could have an additive value to the EuroSCORE, since the baseline ScO<sub>2</sub> could be a predictor of hospital mortality independent of the EuroSCORE.

### Significance of absolute ScO<sub>2</sub> values for outcome prediction

Many studies found links between decrements in ScO<sub>2</sub> during cardiac surgery and postoperative neurological complications [3–12]. However, in these studies, quite inconsistent criteria for cerebral desaturation were used even using the identical INVOS device [3–12]. Further, most studies had limitations, such as small sample sizes (mostly  $n \leq 100$ ). Therefore, no definite criterion is currently available regarding what threshold ScO<sub>2</sub> and/or what decrement in ScO<sub>2</sub> from baseline indicates an abnormal finding during cardiac surgery [1]. However, Schoen et al. revealed, in 231 patients, that the baseline ScO<sub>2</sub> value, the minimal intraoperative ScO<sub>2</sub> value, and the AUC below ScO<sub>2</sub> <50% were associated with postoperative delirium, whereas the relative ScO<sub>2</sub> decrease or the AUC below 80% of the baseline were not [9]. They reported that cutoff values of the baseline ScO<sub>2</sub> and the lowest intraoperative ScO<sub>2</sub> for predicting delirium were 59.5% and 51.0%, respectively [9]. Such results indicated that absolute ScO<sub>2</sub> values rather than relative ScO<sub>2</sub> decrements were more relevant in predicting neurological complications. Further, Heringlake et al. showed, in 1178 patients, that patients with baseline ScO<sub>2</sub> ≤50% were at increased risk for postoperative mortality and those with a preoperative ScO<sub>2</sub> ≤60% were at increased risk for postoperative morbidity [24]. We also found, in 573 patients, that patients with the baseline ScO<sub>2</sub> ≤50.5% and the lowest intraoperative ScO<sub>2</sub> ≤35% were at increased risk for hospital morbidity, and that absolute ScO<sub>2</sub> values, but not relative ScO<sub>2</sub> decrements, could be predictors of hospital mortality. Such results indicated that

absolute ScO<sub>2</sub> values rather than relative ScO<sub>2</sub> decrements were more relevant in predicting postoperative mortality. Hence, low perioperative absolute ScO<sub>2</sub> might help to identify patients at high risk for postoperative adverse events [5, 6, 8, 12], which highlights the clinical significance of absolute ScO<sub>2</sub> values. However, further studies in large cohorts are required to identify best cutoff points of perioperative ScO<sub>2</sub> values for predicting a variety of postoperative complications and mortality.

## Limitations

Our study had several limitations. ScO<sub>2</sub> was measured only with the INVOS device. Therefore, it remains to be known whether our results would be reproducible with other NIRS devices. Further, as this study was conducted in a retrospective fashion, detailed descriptions of postoperative morbidity were omitted, and there might be any problems with measurement accuracy of ScO<sub>2</sub> and other variables. Further, although a low baseline ScO<sub>2</sub> value by itself could be a risk factor for increasing perioperative morbidity and mortality, it remains to be clarified whether low ScO<sub>2</sub> simply identifies patients with severe comorbidities who are at high risk for postoperative complications or it represents a potentially modifiable risk factor.

## Conclusion

In 573 patients undergoing major cardiovascular surgery, the baseline ScO<sub>2</sub> correlated with BNP, Hgb, eGFR, and LVEF. BNP was the most significant influencing factor. Further, ScO<sub>2</sub> correlated with the EuroSCORE. ScO<sub>2</sub> correlated with Hgb, eGFR, BSA, and LVEF in linear manners, while correlating with BNP and the EuroSCORE in exponential manners. The baseline and lowest intraoperative ScO<sub>2</sub> values could predict hospital mortality, independent of the EuroSCORE, and the baseline ScO<sub>2</sub> ≤50.5% and the lowest intraoperative ScO<sub>2</sub> ≤35% were associated with increased hospital mortality. Low baseline ScO<sub>2</sub> values were associated with longer needs for postoperative care and higher hospital mortality. The low baseline ScO<sub>2</sub> was reflective of severity of preoperative systemic comorbidities and was of value for risk stratification in patients undergoing cardiovascular surgery.

## Supporting information

**S1 File.** 'Available data'.  
(XLSX)

## Acknowledgments

We thank all the staff for their assistance in conducting this study. This study received no specific grants from any funding agency in the public, commercial, or not-for-profit sectors.

## Author Contributions

**Conceptualization:** Hiroshi Mukaida.

**Data curation:** Hiroshi Mukaida, Masakazu Hayashida, Makiko Yamamoto.

**Formal analysis:** Hiroshi Mukaida, Satoshi Matsushita.

**Investigation:** Hiroshi Mukaida, Makiko Yamamoto.

**Methodology:** Hiroshi Mukaida, Makiko Yamamoto.

**Supervision:** Atsushi Amano.

**Validation:** Masakazu Hayashida, Satoshi Matsushita, Atsushi Nakamura.

**Writing – original draft:** Hiroshi Mukaida.

**Writing – review & editing:** Masakazu Hayashida, Atsushi Amano.

## References

- Zheng F, Sheinberg R, Yee MS, Ono M, Zheng Y, Hogue CW. Cerebral near-infrared spectroscopy monitoring and neurologic outcomes in adult cardiac surgery patients: a systematic review. *Anesth analg*. 2013; 116: 663–76. <https://doi.org/10.1213/ANE.0b013e318277a255> PMID: 23267000
- Steppan J, Hogue CW Jr. Cerebral and tissue oximetry. *Best Pract Res Clin Anaesthesiol*. 2014; 28: 429–39. <https://doi.org/10.1016/j.bpa.2014.09.002> PMID: 25480772
- Yao FS, Tseng CC, Ho CY, Levin SK, Illner P. Cerebral oxygen desaturation is associated with early postoperative neuropsychological dysfunction in patients undergoing cardiac surgery. *J Cardiothorac Vasc Anesth*. 2004; 18: 552–8. PMID: 15578464
- Reents W, Muellges W, Franke D, Babin-Ebell J, Elert O. Cerebral oxygen saturation assessed by near-infrared spectroscopy during coronary artery bypass grafting and early postoperative cognitive function. *Ann Thorac Surg*. 2002; 74: 109–14. PMID: 12118739
- Hong SW, Shim JK, Choi YS, Kim DH, Chang BC, Kwak YL. Prediction of cognitive dysfunction and patients' outcome following valvular heart surgery and the role of cerebral oximetry. *Eur J Cardiothorac Surg*. 2008; 33: 560–5. <https://doi.org/10.1016/j.ejcts.2008.01.012> PMID: 18272385
- Slater JP, Guarino T, Stack J, Vinod K, Bustami RT, Brown JM 3rd, et al. Cerebral oxygen desaturation predicts cognitive decline and longer hospital stay after cardiac surgery. *Ann Thorac Surg*. 2009; 87: 36–44. <https://doi.org/10.1016/j.athoracsur.2008.08.070> PMID: 19101265
- de Tournay-Jetté E, Dupuis G, Bherer L, Deschamps A, Cartier R, Denault A. The relationship between cerebral oxygen saturation changes and postoperative cognitive dysfunction in elderly patients after coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth*. 2011; 25: 95–104. <https://doi.org/10.1053/j.jvca.2010.03.019> PMID: 20650659
- Schoen J, Husemann L, Tiemeyer C, Lueloh A, Sedemund-Adib B, Berger KU, et al. Cognitive function after sevoflurane- vs propofol-based anaesthesia for on-pump cardiac surgery: a randomized controlled trial. *Br J Anaesth*. 2011; 106: 840–50. <https://doi.org/10.1093/bja/aer091> PMID: 21518736
- Schoen J, Meyerrose J, Paarmann H, Heringlake M, Hueppe M, Berger KU. Preoperative regional cerebral oxygen saturation is a predictor of postoperative delirium in on-pump cardiac surgery patients: a prospective observational trial. *Crit Care*. 2011; 15: R218. <https://doi.org/10.1186/cc10454> PMID: 21929765
- Skhirtladze K, Birkenberg B, Mora B, Moritz A, Ince I, Ankersmit HJ, et al. Cerebral desaturation during cardiac arrest: its relation to arrest duration and left ventricular pump function. *Crit Care Med*. 2009; 37: 471–5. <https://doi.org/10.1097/CCM.0b013e3181953d4c> PMID: 19114911
- Edmonds HL Jr. Protective effect of neuromonitoring during cardiac surgery. *Ann N Y Acad Sci*. 2005; 1053: 12–9. <https://doi.org/10.1196/annals.1344.002> PMID: 16179501
- Murkin JM, Adams SJ, Novick RJ, Quantz M, Bainbridge D, Iglesias I, et al. Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study. *Anesth Analg*. 2007; 104: 51–8. <https://doi.org/10.1213/01.ane.0000246814.29362.f4> PMID: 17179242
- Sørensen H, Secher NH, Siebenmann C, Nielsen HB, Kohl-Bareis M, Lundby C, et al. Cutaneous vasoconstriction affects near-infrared spectroscopy determined cerebral oxygen saturation during administration of norepinephrine. *Anesthesiology*. 2012; 117: 263–70. <https://doi.org/10.1097/ALN.0b013e3182605afe> PMID: 22739762
- Davie SN, Grocott HP. Impact of extracranial contamination on regional cerebral oxygen saturation: a comparison of three cerebral oximetry technologies. *Anesthesiology*. 2012; 116: 834–40. <https://doi.org/10.1097/ALN.0b013e31824c00d7> PMID: 22343469
- Greenberg S, Murphy G, Shear T, Patel A, Simpson A, Szokol J, et al. Extracranial contamination in the INVOS 5100C versus the FORE-SIGHT ELITE cerebral oximeter: a prospective observational cross-over study in volunteers. *Can J Anaesth*. 2016; 63: 24–30. <https://doi.org/10.1007/s12630-015-0451-7> PMID: 26307186
- Yoshitani K, Kawaguchi M, Iwata M, Sasaoka N, Inoue S, Kurumatani N, et al. Comparison of changes in jugular venous bulb oxygen saturation and cerebral oxygen saturation during variations of haemoglobin concentration under propofol and sevoflurane anaesthesia. *Br J Anaesth*. 2005; 94: 341–6. <https://doi.org/10.1093/bja/aei046> PMID: 15591331

17. Yoshitani K, Kawaguchi M, Miura N, Okuno T, Kanoda T, Ohnishi Y, et al. Effects of hemoglobin concentration, skull thickness, and the area of the cerebrospinal fluid layer on near-infrared spectroscopy measurements. *Anesthesiology*. 2007; 106: 458–62. PMID: [17325503](#)
18. Thavasothy M, Broadhead M, Elwell C, Peters M, Smith M. A comparison of cerebral oxygenation as measured by the NIRO 300 and the INVOS 5100 Near-Infrared Spectrophotometers. *Anaesthesia*. 2002; 57: 999–1006. PMID: [12358958](#)
19. Madsen PL, Nielsen HB, Christiansen P. Well-being and cerebral oxygen saturation during acute heart failure in humans. *Clin Physiol*. 2000; 20: 158–64. PMID: [10735984](#)
20. Paquet C, Deschamps A, Denault AY, Couture P, Carrier M, Babin D, et al. Baseline regional cerebral oxygen saturation correlates with left ventricular systolic and diastolic function. *J Cardiothorac Vasc Anesth*. 2008; 22: 840–6. <https://doi.org/10.1053/j.jvca.2008.02.013> PMID: [18834789](#)
21. Kobayashi K, Kitamura T, Kohira S, Torii S, Horai T, Hirata M, Mishima T, Sughimoto K, Ohkubo H, Iri-sawa Y, Matsushiro T, Hayashi H, Miyata Y, Tsuchida Y, Ohtomo N, Miyaji K. Factors associated with a low initial cerebral oxygen saturation value in patients undergoing cardiac surgery. *J Artif Organs*. 2017; 20:110–116. <https://doi.org/10.1007/s10047-016-0941-6> PMID: [28054177](#)
22. Hoshino T, Ookawara S, Goto S, Miyazawa H, Ito K, Ueda Y, et al. Evaluation of cerebral oxygenation in patients undergoing long-term hemodialysis. *Nephron Clin Pract*. 2014; 126: 57–61. <https://doi.org/10.1159/000358432> PMID: [24526002](#)
23. Ito K, Ookawara S, Ueda Y, Goto S, Miyazawa H, Yamada H, et al. Factors affecting cerebral oxygenation in hemodialysis patients: cerebral oxygenation associates with pH, hemodialysis duration, serum albumin concentration, and diabetes mellitus. *PLoS One*. 2015; 10: e0117474. <https://doi.org/10.1371/journal.pone.0117474> PMID: [25706868](#)
24. Heringlake M, Garbers C, Käbler JH, Anderson I, Heinze H, Schön J, et al. Preoperative cerebral oxygen saturation and clinical outcomes in cardiac surgery. *Anesthesiology*. 2011; 114: 58–69. <https://doi.org/10.1097/ALN.0b013e3181fef34e> PMID: [21178669](#)
25. Mariés L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). *Cardiovasc J Afr*. 2013; 24: 286–9. <https://doi.org/10.5830/CVJA-2013-055> PMID: [24217307](#)
26. Forfia PR, Watkins SP, Rame JE, Stewart KJ, Shapiro EP. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. *J Am Coll Cardiol* 2005; 45: 667–71.
27. Maeder MT, Mariani JA, Kaye DM. Hemodynamic determinants of myocardial B-type natriuretic peptide release: relative contributions of systolic and diastolic wall stress. *Hypertension*. 2010; 56: 682–9. <https://doi.org/10.1161/HYPERTENSIONAHA.110.156547> PMID: [20713912](#)
28. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. *Intern Med J*. 2008; 38: 101–13. <https://doi.org/10.1111/j.1445-5994.2007.01454.x> PMID: [18290826](#)
29. Klaar U, Gabriel H, Bergler-Klein J, Pernicka E, Heger M, Mascherbauer J, Rosenhek R, Binder T, Maurer G, Baumgartner H. Prognostic value of serial B-type natriuretic peptide measurement in asymptomatic organic mitral regurgitation. *Eur J Heart Fail*. 2011; 13: 163–9. <https://doi.org/10.1093/eurjhf/hfq189> PMID: [21051463](#)
30. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. *Eur Heart J* 2003; 24: 881–2.
31. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. *Eur J Cardiothorac Surg*. 2012; 41: 734–45. <https://doi.org/10.1093/ejcts/ezs043> PMID: [22378855](#)
32. Jungbauer CG, Kaess B, Buchner S, Birner C, Lubnow M, Resch M, et al. Equal performance of novel N-terminal proBNP (Cardiac proBNP®) and established BNP (Triage BNP®) point-of-care tests. *Biomark Med*. 2012; 6: 789–96. <https://doi.org/10.2217/bmm.12.67> PMID: [23227844](#)
33. Kainuma S, Taniguchi K, Toda K, Shudo Y, Takeda K, Funatsu T, et al. B-type natriuretic peptide response and reverse left ventricular remodeling after surgical correction of functional mitral regurgitation in patients with advanced cardiomyopathy. *J Cardiol*. 2015; 66: 279–85. <https://doi.org/10.1016/j.jjcc.2015.02.015> PMID: [25851471](#)
34. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. *Lancet*. 2003; 362(9380): 316–22. [https://doi.org/10.1016/S0140-6736\(03\)13976-1](https://doi.org/10.1016/S0140-6736(03)13976-1) PMID: [12892964](#)
35. El-Saed A, Voigt A, Shalaby A. Usefulness of brain natriuretic peptide level at implant in predicting mortality in patients with advanced but stable heart failure receiving cardiac resynchronization therapy. *Clin Cardiol*. 2009; 32: E33–8.